Clinical trial
Immunogenicity and Tolerance of Two Strategies of Anti-HAV Vaccination in…
NCT00190242 · Assistance Publique - Hôpitaux de Paris, Other · Completed
Key facts
| NCT number | NCT00190242 |
|---|---|
| Title | Immunogenicity and Tolerance of Two Strategies of Anti-HAV Vaccination in HIV-infected Patients |
| Official title | Study of Immunogenicity of Anti-HAV Immunisation in HIV-1 Infected Patients, Co-infected or Not With HBV and/or HCV. HEP.A.VAC Study. |
| Acronym | HEPAVAC |
| Lead sponsor | Assistance Publique - Hôpitaux de Paris, Other |
| Collaborators | Ensemble contre le SIDA GlaxoSmithKline Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | HIV Infection |
| Intervention type | Drug |
| Interventions | group1, group2 |
| Enrollment | 99 |
| Start date | Jun 1, 2003 |
| Primary completion | Oct 1, 2006 |
| Completion | Oct 1, 2009 |
| First posted | Sep 19, 2005 |
| Last update posted | Dec 16, 2011 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: